Selected research
Industry Research
High Mobility Group Protein B1 Industry Research Report 2026
Market perspective
The global High Mobility Group Protein B1 market was valued at US$ million in 2025 and is projected to reach US$ million by 2032, implying a CAGR of % over 2026–2032.
The North America market for High Mobility Group Protein B1 is projected to increase from US$ million in 2026 to US$ million by 2032, corresponding to a CAGR of % over 2026–2032.
The Europe market for High Mobility Group Protein B1 is projected to rise from US$ million in 2026 to US$ million by 2032, registering a CAGR of % over 2026–2032.
Read the full market overview
The Asia Pacific market for High Mobility Group Protein B1 is expected to grow from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026–2032.
Leading global manufacturers of High Mobility Group Protein B1 include Ribomic Inc, Evec Inc, Dicerna Pharmaceuticals Inc, Cantex Pharmaceuticals Inc and Affibody AB, among others. In 2025, the top three vendors together accounted for approximately % of global revenue.
Report Scope
This report quantifies the global High Mobility Group Protein B1 market in terms of revenue (US$ million) and, where applicable, sales volume (K Units), using 2025 as the base year and providing annual historical and forecast data for 2021–2032.
It standardizes definitions of Types and Applications, harmonizes vendor attribution, and presents comparable time series by company, Type, Application, and region/country, including indicative price bands (US$/K Units) and concentration ratios (CR5/CR10).
The outputs are intended to support strategy development, budgeting, and performance benchmarking for brand owners, manufacturers, retailers, channel partners, and investors; data are structured with consistent units and fields to facilitate integration into internal FP&A and BI systems.
Key Companies & Market Share Insights
This section profiles leading manufacturers, combining 2021–2025 results with a 2026–2032 outlook. It reports revenue, market share, price bands, product and application mix, regional and channel mix, and key developments (M&A, capacity additions, certifications). It also provides global revenue, average price, and—where applicable—sales volume by manufacturer, and calculates CR5/CR10 and rank changes to support comparative benchmarking.
High Mobility Group Protein B1 Market by Company
Ribomic Inc
Evec Inc
Dicerna Pharmaceuticals Inc
Cantex Pharmaceuticals Inc
Affibody AB
High Mobility Group Protein B1 Segment by Type
Dociparstat Sodium
RBM-005
EV-007156
Others
High Mobility Group Protein B1 Segment by Application
Chemotherapy Effects
Cerebral Infarction
Autoimmune Disorders
Others
High Mobility Group Protein B1 Segment by Region
North America
United States
Canada
Europe
Germany
France
U.K.
Italy
Netherlands
Asia-Pacific
China
Japan
South Korea
India
Australia
China Taiwan
Southeast Asia
South America
Mexico
Brazil
Argentina
Middle East & Africa
Turkey
Saudi Arabia
UAE
Key Drivers & Barriers
High-impact rendering factors and drivers have been studied in this report to aid the readers to understand the general development. Moreover, the report includes restraints and challenges that may act as stumbling blocks on the way of the players. This will assist the users to be attentive and make informed decisions related to business. Specialists have also laid their focus on the upcoming business prospects.
Reasons to Buy This Report
1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global High Mobility Group Protein B1 market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.
2. This report will help stakeholders to understand the global industry status and trends of High Mobility Group Protein B1 and provides them with information on key market drivers, restraints, challenges, and opportunities.
3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in volume and value), competitor ecosystem, new product development, expansion, and acquisition.
4. This report stays updated with novel technology integration, features, and the latest developments in the market
5. This report helps stakeholders to gain insights into which regions to target globally
6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of High Mobility Group Protein B1.
7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.
Chapter Outline
Chapter 1: Research objectives, research methods, data sources, data cross-validation;
Chapter 2: Introduces the report scope of the report, executive summary of different market segments (by region, product type, application, etc.), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter 3: Detailed analysis of High Mobility Group Protein B1 manufacturers competitive landscape, price, production and value market share, latest development plan, merger, and acquisition information, etc.
Chapter 4: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product production/output, value, price, gross margin, product introduction, recent development, etc.
Chapter 5: Production/output, value of High Mobility Group Protein B1 by region/country. It provides a quantitative analysis of the market size and development potential of each region in the next six years.
Chapter 6: Consumption of High Mobility Group Protein B1 in regional level and country level. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and production of each country in the world.
Chapter 7: Provides the analysis of various market segments by type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 8: Provides the analysis of various market segments by application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 9: Analysis of industrial chain, including the upstream and downstream of the industry.
Chapter 10: Introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.
Chapter 11: The main points and conclusions of the report.
More report detail
Tables and figures
Scope & coverage.
Types
- Dociparstat Sodium
- RBM-005
- EV-007156
- Others
Applications
- Chemotherapy Effects
- Cerebral Infarction
- Autoimmune Disorders
- Others
Companies covered
- Ribomic Inc
- Evec Inc
- Dicerna Pharmaceuticals Inc
- Cantex Pharmaceuticals Inc
- Affibody AB
Inside the report.
1 Preface
- 1.1 Scope of Report
- 1.2 Reasons for Doing This Study
- 1.3 Research Methodology
- 1.4 Research Process
- 1.5 Data Source
- 1.5.1 Secondary Sources
- 1.5.2 Primary Sources
2 Market Overview
- 2.1 Product Definition
- 2.2 Global Market Growth Prospects
- 2.2.1 Global High Mobility Group Protein B1 Market Size (2021-2032)
- 2.2.2 Global High Mobility Group Protein B1 Sales (2021-2032)
- 2.2.3 Global High Mobility Group Protein B1 Market Average Price (2021-2032)
- 2.3 High Mobility Group Protein B1 by Type
- 2.3.1 Market Value Comparison by Type (2021 VS 2025 VS 2032) & (US$ Million)
- 2.3.2 Dociparstat Sodium
- 2.3.3 RBM-005
- 2.3.4 EV-007156
- 2.3.5 Others
- 2.4 High Mobility Group Protein B1 by Application
- 2.4.1 Market Value Comparison by Application (2021 VS 2025 VS 2032)
- 2.4.2 Chemotherapy Effects
- 2.4.3 Cerebral Infarction
- 2.4.4 Autoimmune Disorders
- 2.4.5 Others
3 Market Competitive Landscape by Manufacturers
- 3.1 Global High Mobility Group Protein B1 Market Competitive Situation by Manufacturers (2021 Versus 2025)
- 3.2 Global High Mobility Group Protein B1 Sales (K Units) of Manufacturers (2021-2026)
- 3.3 Global High Mobility Group Protein B1 Revenue of Manufacturers (2021-2026)
- 3.4 Global High Mobility Group Protein B1 Average Price by Manufacturers (2021-2026)
- 3.5 Global High Mobility Group Protein B1 Industry Ranking, 2024 VS 2025 VS 2026
- 3.6 Global Manufacturers of High Mobility Group Protein B1, Manufacturing Sites & Headquarters
- 3.7 Global Manufacturers of High Mobility Group Protein B1, Product Type & Application
- 3.8 Global Manufacturers of High Mobility Group Protein B1, Established Date
- 3.9 Global High Mobility Group Protein B1 Market CR5 and HHI
- 3.10 Global Manufacturers Mergers & Acquisition
4 Manufacturers Profiled
- 4.1 Ribomic Inc
- 4.1.1 Ribomic Inc Company Information
- 4.1.2 Ribomic Inc Business Overview
- 4.1.3 Ribomic Inc High Mobility Group Protein B1 Sales, Revenue and Gross Margin (2021-2026)
- 4.1.4 Ribomic Inc High Mobility Group Protein B1 Product Portfolio
- 4.1.5 Ribomic Inc Recent Developments
- 4.2 Evec Inc
- 4.2.1 Evec Inc Company Information
- 4.2.2 Evec Inc Business Overview
- 4.2.3 Evec Inc High Mobility Group Protein B1 Sales, Revenue and Gross Margin (2021-2026)
- 4.2.4 Evec Inc High Mobility Group Protein B1 Product Portfolio
- 4.2.5 Evec Inc Recent Developments
- 4.3 Dicerna Pharmaceuticals Inc
- 4.3.1 Dicerna Pharmaceuticals Inc Company Information
- 4.3.2 Dicerna Pharmaceuticals Inc Business Overview
- 4.3.3 Dicerna Pharmaceuticals Inc High Mobility Group Protein B1 Sales, Revenue and Gross Margin (2021-2026)
- 4.3.4 Dicerna Pharmaceuticals Inc High Mobility Group Protein B1 Product Portfolio
- 4.3.5 Dicerna Pharmaceuticals Inc Recent Developments
- 4.4 Cantex Pharmaceuticals Inc
- 4.4.1 Cantex Pharmaceuticals Inc Company Information
- 4.4.2 Cantex Pharmaceuticals Inc Business Overview
- 4.4.3 Cantex Pharmaceuticals Inc High Mobility Group Protein B1 Sales, Revenue and Gross Margin (2021-2026)
- 4.4.4 Cantex Pharmaceuticals Inc High Mobility Group Protein B1 Product Portfolio
- 4.4.5 Cantex Pharmaceuticals Inc Recent Developments
- 4.5 Affibody AB
- 4.5.1 Affibody AB Company Information
- 4.5.2 Affibody AB Business Overview
- 4.5.3 Affibody AB High Mobility Group Protein B1 Sales, Revenue and Gross Margin (2021-2026)
- 4.5.4 Affibody AB High Mobility Group Protein B1 Product Portfolio
- 4.5.5 Affibody AB Recent Developments
5 Global High Mobility Group Protein B1 Market Scenario by Region
- 5.1 Global High Mobility Group Protein B1 Market Size by Region: 2021 VS 2025 VS 2032
- 5.2 Global High Mobility Group Protein B1 Sales by Region: 2021-2032
- 5.2.1 Global High Mobility Group Protein B1 Sales by Region: 2021-2026
- 5.2.2 Global High Mobility Group Protein B1 Sales by Region: 2027-2032
- 5.3 Global High Mobility Group Protein B1 Revenue by Region: 2021-2032
- 5.3.1 Global High Mobility Group Protein B1 Revenue by Region: 2021-2026
- 5.3.2 Global High Mobility Group Protein B1 Revenue by Region: 2027-2032
- 5.4 North America High Mobility Group Protein B1 Market Facts & Figures by Country
- 5.4.1 North America High Mobility Group Protein B1 Market Size by Country: 2021 VS 2025 VS 2032
- 5.4.2 North America High Mobility Group Protein B1 Sales by Country (2021-2032)
- 5.4.3 North America High Mobility Group Protein B1 Revenue by Country (2021-2032)
- 5.4.4 United States
- 5.4.5 Canada
- 5.5 Europe High Mobility Group Protein B1 Market Facts & Figures by Country
- 5.5.1 Europe High Mobility Group Protein B1 Market Size by Country: 2021 VS 2025 VS 2032
- 5.5.2 Europe High Mobility Group Protein B1 Sales by Country (2021-2032)
- 5.5.3 Europe High Mobility Group Protein B1 Revenue by Country (2021-2032)
- 5.5.4 Germany
- 5.5.5 France
- 5.5.6 U.K.
- 5.5.7 Italy
- 5.5.8 Netherlands
- 5.6 Asia Pacific High Mobility Group Protein B1 Market Facts & Figures by Country
- 5.6.1 Asia Pacific High Mobility Group Protein B1 Market Size by Country: 2021 VS 2025 VS 2032
- 5.6.2 Asia Pacific High Mobility Group Protein B1 Sales by Country (2021-2032)
- 5.6.3 Asia Pacific High Mobility Group Protein B1 Revenue by Country (2021-2032)
- 5.6.4 China
- 5.6.5 Japan
- 5.6.6 South Korea
- 5.6.7 India
- 5.6.8 Australia
- 5.6.9 China Taiwan
- 5.6.10 Southeast Asia
- 5.7 South America High Mobility Group Protein B1 Market Facts & Figures by Country
- 5.7.1 South America High Mobility Group Protein B1 Market Size by Country: 2021 VS 2025 VS 2032
- 5.7.2 South America High Mobility Group Protein B1 Sales by Country (2021-2032)
- 5.7.3 South America High Mobility Group Protein B1 Revenue by Country (2021-2032)
- 5.7.4 Mexico
- 5.7.5 Brazil
- 5.7.6 Argentina
- 5.8 Middle East and Africa High Mobility Group Protein B1 Market Facts & Figures by Country
- 5.8.1 Middle East and Africa High Mobility Group Protein B1 Market Size by Country: 2021 VS 2025 VS 2032
- 5.8.2 Middle East and Africa High Mobility Group Protein B1 Sales by Country (2021-2032)
- 5.8.3 Middle East and Africa High Mobility Group Protein B1 Revenue by Country (2021-2032)
- 5.8.4 Turkey
- 5.8.5 Saudi Arabia
- 5.8.6 UAE
6 Segment by Type
- 6.1 Global High Mobility Group Protein B1 Sales by Type (2021-2032)
- 6.1.1 Global High Mobility Group Protein B1 Sales by Type (2021-2032) & (K Units)
- 6.1.2 Global High Mobility Group Protein B1 Sales Market Share by Type (2021-2032)
- 6.2 Global High Mobility Group Protein B1 Revenue by Type (2021-2032)
- 6.2.1 Global High Mobility Group Protein B1 Sales by Type (2021-2032) & (US$ Million)
- 6.2.2 Global High Mobility Group Protein B1 Revenue Market Share by Type (2021-2032)
- 6.3 Global High Mobility Group Protein B1 Price by Type (2021-2032)
7 Segment by Application
- 7.1 Global High Mobility Group Protein B1 Sales by Application (2021-2032)
- 7.1.1 Global High Mobility Group Protein B1 Sales by Application (2021-2032) & (K Units)
- 7.1.2 Global High Mobility Group Protein B1 Sales Market Share by Application (2021-2032)
- 7.2 Global High Mobility Group Protein B1 Revenue by Application (2021-2032)
- 7.2.1 Global High Mobility Group Protein B1 Sales by Application (2021-2032) & (US$ Million)
- 7.2.2 Global High Mobility Group Protein B1 Revenue Market Share by Application (2021-2032)
- 7.3 Global High Mobility Group Protein B1 Price by Application (2021-2032)
8 Value Chain and Sales Channels Analysis of the Market
- 8.1 High Mobility Group Protein B1 Value Chain Analysis
- 8.1.1 High Mobility Group Protein B1 Key Raw Materials
- 8.1.2 Raw Materials Key Suppliers
- 8.1.3 High Mobility Group Protein B1 Production Mode & Process
- 8.2 High Mobility Group Protein B1 Sales Channels Analysis
- 8.2.1 Direct Comparison with Distribution Share
- 8.2.2 High Mobility Group Protein B1 Distributors
- 8.2.3 High Mobility Group Protein B1 Customers
9 Global High Mobility Group Protein B1 Analyzing Market Dynamics
- 9.1 High Mobility Group Protein B1 Industry Trends
- 9.2 High Mobility Group Protein B1 Industry Drivers
- 9.3 High Mobility Group Protein B1 Industry Opportunities and Challenges
- 9.4 High Mobility Group Protein B1 Industry Restraints
10 Report Conclusion
11 Disclaimer
GET THE RESEARCH
Choose your license.
Choose who needs access.
All options are for this report and research series.
PDF by email within 3–5 working days after payment confirmation.
Talk to an analyst